Identification of high-risk human papillomavirus (hrHPV)-associated genes in early stage cervical squamous cell carcinomas

Journal of International Medical Research

Volumn 39, Issue 3, 2011, Pages 712-728

  Hu, Y ^a   Liu, Y ^a   Liu, C B ^a   Ling, Z Q ^b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

cDNA microarray; Cervical squamous carcinoma (CSCC); Gene expression; High risk human papillomavirus (hrHPV); Human papillomavirus genotyping

Indexed keywords

COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; INTERLEUKIN 1ALPHA; LAMININ GAMMA1; SOMATOMEDIN BINDING PROTEIN 6; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CARCINOGENESIS; CDKN2A GENE; CELL ADHESION; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; EGFR GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IGFBP6 GENE; IL1A GENE; LAMC1 GENE; MMP9 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TGFB1 GENE; UPREGULATION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX EPITHELIUM;

EID: 80052242479     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900303     Document Type: Article

References (59)

1. Gien LT, Covens A: Fertility-sparing options for early stage cervical carcinoma. Gynecol Oncol 2010; 117: 350-357.
2. Louie KS, de Sanjose S, Mayaud P: Epidemiology and prevention of human papillomavirus and cervical carcinoma in sub-Saharan Africa: a comprehensive review. Trop Med Int Health 2009; 14: 1287-1302.
3. Shapley M, Jordan J, Croft PR: A systematic review of postcoital bleeding and risk of cervical carcinoma. Br J Gen Pract 2006; 56: 453-460.
4. Chamot E, Kristensen S, Stringer JS, et al: Are treatments for cervical precancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs? A systematic review. BMC Womens Health 2010; 10: 11.
5. Montgomery K, Bloch JR: The human papillomavirus in women over 40: implications for practice and recommendations for screening. J Am Acad Nurse Pract 2010; 22: 92-100.
6. Sehgal A, Singh V: Human papillomavirus infection (HPV) & screening strategies for cervical carcinoma. Indian J Med Res 2009; 130: 234-240.
7. Georgieva S, Iordanov V, Sergieva S: Nature of cervical carcinoma and other HPV-associated cancers. J BUON 2009; 14: 391-398.
8. Trottier H, Burchell AN: Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009; 12: 291-307.
9. McKenzie ND, Kobetz EN, Hnatyszyn J, et al: Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types. Gynecol Oncol 2010; 116: 572-577.
10. Steben M, Duarte-Franco E: Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 2007; 107(2 suppl 1): S2-S5.
11. Bosch FX, de Sanjosé S: The epidemiology of human papillomavirus infection and cervical carcinoma. Dis Markers 2007; 23: 213-227.
12. Muñoz N, Bosch FX, de Sanjosé S, et al: Epidemiologic classification of human papillomavirus types associated with cervical carcinoma. N Engl J Med 2003; 348: 518-527.
13. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical carcinoma worldwide. J Pathol 1999; 189: 12-19.
14. Perou CM, Jeffrey SS, van de Rijn M, et al: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999; 96: 9212-9217.
15. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
16. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
17. Ross DT, Scherf U, Eisen MB, et al: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 227-235.
18. Welsh JB, Zarrinkar PP, Sapinoso LM, et al: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001; 98: 1176-1181.
19. Santin AD, Zhan F, Bignotti E, et al: Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical carcinomas and normal cervical epithelium: identification of novel candidate molecular markers for cervical carcinoma diagnosis and therapy. Virology 2005; 331: 269-291.
20. Ling ZQ, Sugihara H, Tatsuta T, et al: Optimization of comparative expressed sequence hybridization for genome-wide expression profiling at chromosome level. Cancer Genet Cytogenet 2007; 175: 144-153.
21. Tsubosa Y, Sugihara H, Mukaisho K, et al: Effects of degenerate oligonucleotide-primed polymerase chain reaction amplification and labeling methods on the sensitivity and specificity of metaphase- and array-based comparative genomic hybridization. Cancer Genet Cytogenet 2005; 158: 156-166.
22. Aoyagi K, Tatsuta T, Nishigaki M, et al: A faithful method for PCR-mediated global mRNA amplification and its integration into microarray analysis on laser-captured cells. Biochem Biophys Res Commun 2003; 300: 915-920.
23. de Wilde J, Wilting SM, Meijer CJ, et al: Gene expression profiling to identify markers associated with deregulated hTERT in HPVtransformed keratinocytes and cervical cancer. Int J Cancer 2008; 122: 877-888.
24. Dakhova O, Ozen M, Creighton CJ, et al: Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res 2009; 15: 3979-3989.
25. Lando M, Holden M, Bergersen LC, et al: Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet 2009; 5: e1000719.
26. Pyeon D, Newton MA, Lambert PF, et al: Fundamental differences in cell cycle deregulation in human papillomaviruspositive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-4619.
27. Hudelist G, Czerwenka K, Singer C, et al: cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study. Cancer Genet Cytogenet 2005; 158: 35-42.
28. Manavi M, Hudelist G, Fink-Retter A, et al: Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Gynecol Oncol 2007; 105: 418-426.
29. Narisawa-Saito M, Handa K, Yugawa T, et al: HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes. Oncogene 2007; 26: 2988-2996.
30. Ahn GO, Brown JM: Matrix metalloproteinase- 9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008; 13: 193-205.
31. Bergers G, Brekken R, McMahon G, et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-744.
32. Rauvala M, Aglund K, Puistola U, et al: Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression. Int J Gynecol Cancer 2006; 16: 1297-1302.
33. Figueira RC, Gomes LR, Neto JS, et al: Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009; 9: 20.
34. Libra M, Scalisi A, Vella N, et al: Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 2009; 34: 897-903.
35. Sato T, Sakai T, Noguchi Y, et al: Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 2004; 92: 47-56.
36. Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, et al: Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res 2007; 27: 2753-2758.
37. Quelle DE, Zindy F, Ashmun RA, et al: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
38. Sano T, Masuda N, Oyama T, et al: Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol Int 2002; 52: 375-383.
39. INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep™ smears. J Clin Pathol 2003; 56: 56-63.
40. Fukushima Y, Pikkarainen T, Kallunki T, et al: Isolation of a human laminin B2 (LAMB2) cDNA clone and assignment of the gene to chromosome region 1q25-q31. Cytogenet Cell Genet 1988; 48: 137-141.
41. Yurchenco PD, Patton BL: Developmental and pathogenic mechanisms of basement membrane assembly. Curr Pharm Des 2009; 15: 1277-1294.
42. Durbeej M: Laminins. Cell Tissue Res 2010; 339: 259-268.
43. Kohlberger P, Beneder Ch, Horvat R, et al: Immunohistochemical expression of laminin-5 in cervical intraepithelial neoplasia. Gynecol Oncol 2003; 89: 391-394.
44. Habermann JK, Hellman K, Freitag S, et al: A recurrent gain of chromosome arm 3q in primary squamous carcinoma of the vagina. Cancer Genet Cytogenet 2004; 148: 7-13.
45. Movva S, Arias-Pulido H, Chavez A, et al: Expression of the epidermal growth factor receptor (EGFR) pathway in cervical cancer (CC) patients (pts). J Clin Oncol 2009; 27(suppl): abstract 5519 [ASCO Annual Meeting Abstracts Part 1].
46. Kim YT, Park SW, Kim JW: Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol 2002; 87: 84-89.
47. Noh JM, Park W, Huh SJ, et al: Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma. J Gynecol Oncol 2009; 20: 215-220.
48. Geiger T, Levitzki A: Loss of robustness and addiction to IGF1 during early keratinocyte transformation by human papilloma virus 16. PLoS One 2007; 2: e605.
49. Zur Hausen H: Viruses in human cancer. Science 1991; 254: 1167-1173.
50. Zur Hausen H: Viruses in human cancers. Eur J Cancer 1999; 35: 1878-1885.
51. Liu WK, Jiang XY, Zhang MP, et al: The relationship between HPV16 and expression of cyclooxygenase-2, P53 and their prognostic roles in esophageal squamous cell carcinoma. Eur J Gastroenterol Hepatol 2010; 22: 67-74.
52. Burk RD, Chen Z, Van Doorslaer K: Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics 2009; 12: 281-290.
53. Krawczyk E, Suprynowicz FA, Sudarshan SR, et al: Membrane orientation of the human papillomavirus type 16 E5 oncoprotein. J Virol 2010; 84: 1696-1703.
54. Di Domenico F, Foppoli C, Blarzino C, et al: Expression of human papilloma virus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity. J Exp Clin Cancer Res 2009; 28: 4.
55. Johnston D, Hall H, DiLorenzo TP, et al: Elevation of the epidermal growth factor receptor and dependent signaling in human papillomavirus-infected laryngeal papillomas. Cancer Res 1999; 59: 968-974.
56. Lazarczyk M, Cassonnet P, Pons C, et al: The EVER proteins as a natural barrier against papilloma - viruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009; 73: 348-370.
57. Conrad M, Goldstein D, Andresson T, et al: The E5 protein of HPV 6, but not HPV 16, associates efficiently with cellular growth factor receptors. Virology 1994; 200: 796-800.
58. Hwang ES, Nottoli T, Dimaio D: The HPV16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology 1995; 211: 227-233.
59. Wan F, Miao X, Quraishi I, et al: Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer. Int J Cancer 2008; 123: 32-40.